

**POPULATION**

N = 5,988  
HFpEF patients with EF  
>40%

**INTERVENTION**

Empagliflozin  
10mg daily

**COMPARATOR**

Placebo

**PRIMARY ENDPOINT: CV death or HF hospitalization**

**HR 0.79**

**p <0.001**

95% CI: 0.69-0.90

**Safety Findings**

**Limitations**

**Clinical Implications: First therapy to show benefit in HFpEF**